European Approvals in Follicular Lymphoma and Melanoma, NSCLC Advancements, and Disappointing Phase II Results in NHL

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

Simulations Improve CAR T-Cell Therapy Understanding and Administration Confidence